MedPath

Amlodipine

Generic Name
Amlodipine
Brand Names
Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
Drug Type
Small Molecule
Chemical Formula
C20H25ClN2O5
CAS Number
88150-42-9
Unique Ingredient Identifier
1J444QC288

Overview

Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers . Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .

Background

Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers . Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .

Indication

Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions : • Hypertension • Coronary artery disease • Chronic stable angina • Vasospastic angina (Prinzmetal’s or Variant angina) • Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%

Associated Conditions

  • Cardiovascular Events
  • Chronic Stable Angina Pectoris
  • Coronary Artery Disease (CAD)
  • Homozygous Familial Hypercholesterolaemia (HoFH)
  • Hypertension
  • Hypertension, Essential Hypertension
  • Mixed Dyslipidemias
  • Primary Hypercholesterolemia
  • Vasospastic Angina

FDA Approved Products

Amlodipine Besylate and Benazepril Hydrochloride
Manufacturer:BluePoint Laboratories
Route:ORAL
Strength:2.5 mg in 1 1
Approved: 2023/05/03
NDC:68001-132
Amlodipine Besylate and Benazepril Hydrochloride
Manufacturer:BluePoint Laboratories
Route:ORAL
Strength:5 mg in 1 1
Approved: 2023/05/03
NDC:68001-134
Amlodipine Besylate and Benazepril Hydrochloride
Manufacturer:BluePoint Laboratories
Route:ORAL
Strength:5 mg in 1 1
Approved: 2023/05/03
NDC:68001-135
Amlodipine Besylate
Manufacturer:American Health Packaging
Route:ORAL
Strength:5 mg in 1 1
Approved: 2023/08/29
NDC:60687-488
Exforge
Manufacturer:Novartis Pharmaceuticals Corporation
Route:ORAL
Strength:10 mg in 1 1
Approved: 2018/12/17
NDC:0078-0491

Singapore Approved Products

AMLOTENS TABLET 10MG
Manufacturer:Sanofi Ilac Sanayi ve Ticaret Anonim Sirketi, SIEGFRIED LTD, SIEGFRIED MALTA LTD
Form:TABLET
Strength:10 mg
Online:Yes
Approved: 2010/04/09
Approval:SIN13785P
NORVASC TABLET 5 mg
Manufacturer:Pfizer Pharmaceuticals LLC (bulk product manufacturer), Pfizer Manufacturing Deutschland GmbH (primary & secondary packager)
Form:TABLET
Strength:5 mg
Online:Yes
Approved: 1990/12/27
Approval:SIN05277P
AMCAD 5 TABLET 5 mg
Manufacturer:CADILA PHARMACEUTICALS LIMITED
Form:TABLET
Strength:5 mg
Online:Yes
Approved: 2014/03/27
Approval:SIN14529P
ACTAPIN TABLET 5MG
Manufacturer:PT Actavis Indonesia
Form:TABLET
Strength:5 mg
Online:Yes
Approved: 2008/08/25
Approval:SIN13537P
ANLODIN TABLET 5MG
Manufacturer:Y.S.P. INDUSTRIES (M) SDN. BHD.
Form:TABLET
Strength:5mg
Online:Yes
Approved: 2014/09/22
Approval:SIN14630P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath